Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
The facility sets a new benchmark in respiratory diagnostics
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
